Mankind Pharma Inks Exclusive India Deal for Insulin Degludec

NEW DELHI — Domestic pharmaceutical major Mankind Pharma has executed an exclusive in-licensing and commercialization agreement with China-based biopharmaceutical firm Chongqing Chenan Biopharmaceutical Co., Ltd. to market two advanced insulin analogues—Insulin Degludec and an Insulin Degludec plus Insulin Aspart combination—in India. Announced in corporate regulatory disclosures, the commercial transaction marks a significant step in Mankind Pharma's strategy to scale its chronic therapy pipeline and address rising clinical demand in the domestic injectable diabetes segment.

Commercial Terms and Portfolio Integration

Under the terms of the exclusive agreement, Mankind Pharma secures sole marketing, distribution, and commercialization rights within the Indian territory for both formulations developed by Chongqing Chenan Biopharmaceutical.

The deal covers two distinct biological assets:

• Insulin Degludec: An ultra-long-acting basal insulin analogue designed to provide stable, consistent glycemic control over an extended duration of up to 42 hours with reduced risk of nocturnal hypoglycemia.

• Insulin Degludec + Insulin Aspart Combination: A co-formulation integrating basal coverage with a rapid-acting prandial component to address mealtime glycemic spikes in a single injection.

Mankind Pharma will deploy its domestic supply chain network and extensive physician engagement infrastructure to commercialize the therapies across urban and tier-2 healthcare markets following requisite regulatory approvals.

Therapeutic Expansion in Chronic Care

India represents one of the largest global diabetes burdens, with over 100 million diagnosed individuals requiring long-term glycemic management. The addition of advanced insulin analogues allows Mankind Pharma to bridge a vital therapeutic gap between oral anti-diabetic formulations and conventional human insulins.

Securing access to second-generation basal insulins and fixed-ratio co-formulations positions the drugmaker to capture growing market share in high-barrier injectable therapies. Industry analysts observe that chronic therapy segments offer higher gross margins and recurring prescription volumes compared to acute therapeutic categories, reinforcing operating cash flow resilience.

Strategic Significance for Cross-Border Biologics

The agreement highlights an accelerating trend of Indian pharmaceutical manufacturers partnering with Chinese biotechnology innovators to source complex biologics and biosimilar assets. By in-licensing late-stage and commercial-ready formulations, Mankind Pharma mitigates upfront clinical development risks while shortening domestic time-to-market.

The transaction represents a broader strategic push by domestic drugmakers to diversify their biosimilar pipelines through global alliances, balancing indigenous research capabilities with specialized external biopharmaceutical platforms.

Official Sources Section

Regulatory information and corporate statements concerning this transaction were sourced from statutory disclosures submitted by Mankind Pharma Ltd. to the National Stock Exchange of India and the BSE Limited, alongside statutory compliance frameworks administered by the Securities and Exchange Board of India and therapeutic guidelines from the Central Drugs Standard Control Organisation.

Quote Section

According to official company statements:

"China is rapidly emerging as a hub for innovative biopharmaceutical assets. Building on our partnerships for Insulin Aspart and Insulin Degludec, we remain focused on expanding our in-licensing pipeline from China," stated Atish Majumdar, Senior President – Sales and Marketing at Mankind Pharma. "This partnership reinforces our commitment to expanding access to advanced therapies for patients in India while further strengthening our presence in the injectable diabetes segment."

Why It Matters

The licensing pact significantly lowers barriers for Indian diabetes patients to access next-generation basal and combination insulin therapies, which often command premium pricing under multinational monopolies. For investors, the agreement solidifies Mankind Pharma’s transition into high-value chronic therapies and expands its competitive moat against domestic peers in specialty biopharmaceuticals.

Key Facts at a Glance

• Licensing Entity: Mankind Pharma Ltd. (India).

• Innovator Partner: Chongqing Chenan Biopharmaceutical Co., Ltd. (China).

• Licensed Products: Insulin Degludec and Insulin Degludec + Insulin Aspart combination.

• Scope & Geography: Exclusive marketing and commercialization rights in India.

• Therapeutic Focus: Chronic diabetes management and injectable insulin analogues.

Frequently Asked Questions

What products are included under the Mankind Pharma licensing agreement?

The agreement covers exclusive commercialization rights in India for two therapies: the basal analogue Insulin Degludec and the premixed Insulin Degludec + Insulin Aspart combination.

Who is the developer of these insulin therapies?

The biopharmaceutical products were developed by China-based Chongqing Chenan Biopharmaceutical Co., Ltd.

How does Insulin Degludec differ from conventional insulins?

Insulin Degludec is an ultra-long-acting basal insulin that offers an extended duration of action with lower intra-day variability and reduced risk of nocturnal hypoglycemia compared to earlier basal formulations.

What is the strategic objective of this agreement for Mankind Pharma?

The partnership aims to expand Mankind Pharma's footprint in the high-margin chronic diabetes segment by providing cost-competitive, advanced injectable therapies to the Indian healthcare market.

Source: BSE India Corporate Announcements | National Stock Exchange of India | Securities and Exchange Board of India